Great Bay Bio, a Hong Kong CRO, Closes $15 Million Round for AI-based Bioprocessing

Great Bay Bio, a Hong Kong CRO developing AI-based bioprocessing platforms, closed a $15 million Pre-Series B funding led by Tiger Jade Capital. Tiger Jade was seeded by China’s TigerMed, a clinical CRO with clients who may need GBB’s services. GBB will use the funds to advance its AI-based bioprocessing platforms, build production facilities and form a global commercial development team. Also participating in the funding were AEF Greater Bay Area Fund (managed by Gobi Partners GBA), Vectr Ventures and an unnamed MNC.